Corporate Profile

Portage Biotech (NASDAQ: PRTG) is a clinical-stage immuno-oncology company advancing first-in-class therapies that target known checkpoint resistance pathways to achieve durable treatment response and improve quality of life for patients with cancer. We aim to revolutionize cancer research and development and have created a model dedicated to the advancement of diverse drug platforms, bolstered by proven practices from drug discovery veterans and a strong industry network. The result is a viable product development strategy that supports commercial potential and company growth.

Portage executes the development process and creates strategies to guide novel immuno-oncology assets and asset combinations from bench through human proof of concept. Our team of scientists, clinicians and pharma-experienced executives have a long history of success, collectively contributing to five oncology drug approvals and creating high-value exits. We reduce the risks associated with early clinical development through more efficient capital management and scientific oversight, and our fail-fast approach enables us to continuously review hundreds of assets and asset combinations, selecting only the most promising to advance. Currently, our portfolio consists of five diverse technology platforms, with 10 products currently in preclinical or clinical development.

Stock Quote



Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

14 Sep '22
--The Company Highlights its Clinical Strategy for its Adenosine and iNKT Platforms-- --Clinical Development Goals are Focused on Producing Phase 1b/Phase 2 Efficacy Readouts in Multiple Tumor Types Over the Next two Years-- WESTPORT, Conn. , Sept. 14, 2022 (GLOBE NEWSWIRE) -- Portage Biotech
08 Sep '22
WESTPORT, Conn. , Sept. 08, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today announced that the Company’s management team will be presenting at the following upcoming
29 Aug '22
--Robust Pipeline Now Includes Five Clinical-Stage Small Molecule Immuno-Oncology Assets, Including Invariant Natural Killer T Cell (iNKT) Agonists and Adenosine Antagonists-- ---Cash Runway for New and Current Programs Potentially Extended into 2024-- WESTPORT, Conn. , Aug.